Contents

Search

tafluprost ophthalmic (Zioptan)

FDA-approved Feb 10, 2012 Indications: - increased intraocular pressure - open-angle glaucoma Contraindications: - pregnancy category C Dosage: - 1 drop in affected eye(s) once daily in the evening [2] ophthalmic solution 0.0015% Adverse effects: - conjunctival hyperemia (4-20%) - darkening of the iris (may be permanent) - darkening of the eyelid (may be reversible) - eyelash growth Mechanism of action: - fluorinated analog of prostaglandin F2-alpha - prostaglandin F2-alpha receptor agonists are throught to reduce intraocular pressure by increasing uveosceral outflow [2]

General

tafluprost ophthalmic agent (eyedrops)

Database Correlations

PUBCHEM correlations

References

  1. FDA News Release: Feb 14, 2012 FDA approves Zioptan to treat elevated eye pressure http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291966.htm
  2. Zioptan prescribing information Merck Sharp & Dohme http://www.merck.com/product/usa/pi_circulars/z/zioptan/zioptan_pi.pdf